I-MAB - AMERICAN DEPOSITARY SHARES

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

23 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

14 4 2021 07:30:00 提供 Nasdaq GlobeNewswire

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

06 4 2021 07:00:02 提供 Nasdaq GlobeNewswire

I-Mab Announces Upcoming Participation at April Conferences

31 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

30 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

29 3 2021 06:00:01 提供 Nasdaq GlobeNewswire

I-Mab to Host 2021 R&D Day

24 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse

19 3 2021 15:20:00 提供 Nasdaq GlobeNewswire

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

11 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

10 3 2021 07:00:01 提供 Nasdaq GlobeNewswire